Ben Osborn

Whilst we are seeing a deflationary impact YoY across generic price tenders, the overall costs versus reimbursement and number of lines being dispensed at a loss continues to be a real concern for contractors. Get in touch with us today to see if we can help navigate these complexities and support your business.

10

We are in the best of times and worst of times in precision healthcare. Those of us who have witnessed the rise (and sometimes fall) of novel business models over the past 2 decades observe how the convergence of precision technology -tests - treatments- devices- alongside the power of unlocked patient level data, are transforming patients lives. But it is not enough!..... We need to rethink the economics of precision healthcare to both drive faster precision medicine adoption but also to re-architect the emerging business models which will sustain long term change

61

1 Comment

As we pour over the implications for the life sciences sector here in the UK coming out of today’s budget, a few things have jumped out at me: 📈 💊 Rise in spending for healthcare As one of the largest suppliers of medicines to the NHS, at Teva we see and recognise the constant pressure of the demand put upon the NHS. A 3.4% increase in NHS resource is therefore welcome. If the NHS is to move to being more focused on prevention and earlier intervention, then the dedicated funding for new surgical hubs, more diagnostic scanners, and more radiotherapy provision, are smart investments in the future of our health service. It's important that these additional funds also reach our local community pharmacies, who have seen rising costs and financial pressures for some time. Pharmacies are on the front lines delivering vital healthcare services to patients up and down the country, and we should be doing all that we can to to make sure they can continue their important work in a sustainable way. ✊ 🔬 Supporting innovation, R&D and manufacturing The other thing which caught my eye from a life sciences perspective is the focus on R&D as a way to encourage investment, by continuing to incentivise the work of our world-leading sector. Protecting the £520m Life Sciences Innovative Manufacturing Fund is good news. It’s encouraging to see that the Government will specifically allocate £70 million to the fund in 2025-26, ensuring that it is underway this year. This support encourages global companies to invest here in UK manufacturing whilst demonstrating how the country is continuing to build its capability as the biggest life sciences hub outside of the US. Let’s not forget this was also a hugely important moment for many women and girls up and down the country – seeing our first ever female Chancellor at the despatch box. No matter your politics or what you think of the content of the budget itself, I’m sure we can all agree that is something worth celebrating. #UKBudget #RachelReeves #LifeSciences #TevaUK

48

Glad to see this piece from Rippon in the New Statesman, urging the new Government to take action to ensure patients in the UK are front of the queue for new medicines. A really interesting read on the implications of the current situation, and opportunities for change. In particular, there is a clear need for the new Labour Government to champion reform that ensures access to multi-indication medicines. By addressing this and other challenges, the system will be set up to receive future innovations and get them to patients faster. #HealthcareInnovation #PatientAccess #LifeSciences #SanofiUK #NHS #IndicationBasedPricing

16

More exciting news on GLP-1 agonists: At a time when you think the excitement could not be any higher, we hear even more promising news about clinical use of GLP-1 agonists.  “The Times” published an article this morning (May 14) with these key messages: 1. Millions of middle-aged Britons should be routinely prescribed weight-loss injections to cut their risk of heart attacks and strokes by a fifth, according to a trial set to revolutionise medical practice. 2. The largest study ever into semaglutide, also known as Ozempic or Wegovy, found the drug cuts heart disease deaths by about 20 per cent even if people don’t lose weight. 3. The results — presented at the European Congress on Obesity in Venice — were hailed as the biggest medical breakthrough since the introduction of statins in the 1990s. A link to the publication in Nature Medicine and a link to the clinical study named SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity) is attached below. Key findings are as follows: 1. The trial involved 17,604 adults over the age of 45 who had heart disease — a condition that affects 7.6 million in the UK — or had had a heart attack or stroke. All were overweight or obese, but none had diabetes. Half were given weekly semaglutide injections and the rest a placebo.  2. Over a trial period of three years and four months, the group who took semaglutide had a 20 per cent lower risk of heart attack, stroke or death from heart disease and also lost nine per cent of their body weight on average. 3. The drug delivered heart benefits regardless of how much weight people lost. Times articles: https://lnkd.in/gwHVj3P6 https://lnkd.in/gSk-HQTV Clinical results: https://lnkd.in/gvAmaBY8 https://lnkd.in/gAJEWPZF News: https://lnkd.in/gyDZ8wGN https://lnkd.in/gF_UK9W8 https://lnkd.in/gximb9S6 https://lnkd.in/gfqvZFd9 https://lnkd.in/g-pDYRJp

64

2 Comments

A Brighter Future For Lupus Patients: At AstraZeneca, we’re advancing our understanding of the underlying drivers of immune-mediated diseases, with the goal of making clinical remission a reality for more patients. In diseases like lupus, where care options have been historically limited, change to existing care standards are needed to make this possible.   In addition to discussing the latest progress with the rheumatology community at the EULAR Congress this week, I had an insightful discussion with Dr. Marta Mosca and Pat Wildman on the current state of lupus care and the path forward. Take a read: https://lnkd.in/eHqmZEEE #EULAR2024

45

1 Comment

With New York Climate Week and the UN General Assembly underway, it’s essential we recognise not only the devastating impact on individuals and their families but also the environmental impacts of chronic kidney disease (CKD). Dialysis, a lifesaving intervention for late-stage CKD, consumes >169 billion litres of water and generates 1 billion kg of waste each year. By slowing or halting the progression of CKD, we have the opportunity to improve quality of life for patients and reduce the significant burden that late-stage treatment places on our environment. Through the adoption of health policies that enable early CKD diagnosis and access to treatment and care, we can limit the devastating impacts of the disease on patients and our planet. Together we can secure a more sustainable future. Every voice counts. Help to make the change for patients and the environment by signing up here: https://lnkd.in/dn33RcV8 #ForKidneyHealth #ClimateWeekNYC #UNGA79

9

At AstraZeneca, we're continuously innovating to advance care for complex immune-mediated diseases like cutaneous lupus erythematosus (CLE) and idiopathic inflammatory myopathies (IIM). By targeting the underlying drivers of the disease we’re working to optimise care, moving beyond symptom management to disease modification, remission and one day, even cure in immune-mediated diseases. Learn more: https://lnkd.in/eW--SEs3.

4